Kennedy, Sonya R.
Lafond, Maxime
Haworth, Kevin J.
Escudero, Daniel Suarez
Ionascu, Dan
Frierson, Brion
Huang, Shaoling
Klegerman, Melvin E.
Peng, Tao
McPherson, David D.
Genstler, Curtis
Holland, Christy K.
Funding for this research was provided by:
National Institutes of Health (R01 HL135092, R01 HL135092, R01 HL135092, R01 HL135092, R01 HL135092, R01 HL135092, R01 HL135092, R01 HL135092, R01 HL135092, R01 HL135092, R01 HL135092, R01 HL135092)
Article History
Received: 20 September 2022
Accepted: 7 April 2023
First Online: 16 April 2023
Competing interests
: Boston Scientific provided the EkoSonic Endovascular System control unit and catheters. C.G. is a retired employee and shareholder of Boston Scientific Inc, and CKH and KJH are consultants with Boston Scientific Inc. S.H., M.E.K. and D.D.M. are shareholders and board members of Zymo Pharmaceuticals, LLC. All other co-authors have no conflicts of interest to disclose.